<DOC>
	<DOCNO>NCT01887717</DOCNO>
	<brief_summary>This two-arm , open-label , prospective , multi-center , randomize , active-controlled clinical trial ass efficacy safety TheraSphere comparison standard care therapy ( sorafenib ) treatment patient inoperable liver cancer blockage portal vein .</brief_summary>
	<brief_title>Efficacy Evaluation TheraSphere Treat Inoperable Liver Cancer With Blockage Portal Vein</brief_title>
	<detailed_description>The objective phase III , prospective randomize trial determine whether TheraSphere provide meaningful benefit survival comparison standard care ( sorafenib ) patient good hepatic function advance hepatocellular carcinoma ( HCC ) associate portal vein thrombosis ( PVT ) . This open-label prospective , multi-center , randomize , control clinical trial evaluate use TheraSphere compare standard-of-care sorafenib alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients 18 year age , regardless race gender Advanced unresectable hepatocellular carcinoma branch portal vein thrombosis ( confirm noninvasive criterion EASL/AASLD , mandatory histology noncirrhotic patient ) ; naive recurrent HCC curative treatment ( &gt; 6 month randomization ) Unilobar disease Child Pugh A Tumor volume ≤ 70 % liver volume ( determined visual estimation ) At least one unidimensional HCC target lesion assessable CT MRI accord RECIST 1.1 ECOG Performance Status 01 Platelets ≥ 50 X 10³/µL WBC ≥ 1.5 X10³/µL AST/ALT ≤ 5 X upper limit normal Creatinine ≤ 2.0 mg/dL Life expectancy &gt; 3 month Signed informed consent Confirmed extra hepatic metastasis . Patients indeterminate hepatic hilar lymph nod 2.5 cm great dimension , indeterminate lung nodule ( single lesion 11.5 cm , multiple small lesion total diameter ≤ 2 cm ) may include metastatic disease deem unlikely Known contraindication standardofcare sorafenib include allergic reaction , pill swallow difficulty , uncontrolled hypertension history cardiac disease , significant GI bleed within 30 day , renal failure include dialysis Evidence hepatic vein invasion caval thrombosis Evidence chronic obstructive pulmonary disease Indication possible curative treatment multidisciplinary assessment ( surgery , ablation , transplantation ) Previous treatment sorafenib 4 week previous 2 month ; prior sorafenibrelated toxicity Initiation antitumor therapy include chemotherapy investigational drug treatment within 30 day begin study Prior TACE &lt; 6 month prior screen phase case patient progress intermediate advanced stage due occurrence PVT Patients transplant list History organ allograft Contraindications angiography selective visceral catheterization History severe allergy intolerance contrast agent , narcotic , sedative atropine manage medically Prior external beam radiation therapy liver Evidence continue adverse effect prior therapy Active GI bleed bleed diathesis coagulopathy correctable usual therapy hemostatic agent Evidence disease condition would place patient undue risk preclude safe use TheraSphere treatment Females childbearing potential must negative serum test Participation concurrent clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>portal vein thrombosis</keyword>
</DOC>